Hims & Hers Health, Inc. (NYSE:HIMS) Stock Position Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 14.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,909,233 shares of the company's stock after selling 509,252 shares during the quarter. Nuveen Asset Management LLC owned approximately 1.33% of Hims & Hers Health worth $70,345,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in HIMS. Means Investment CO. Inc. boosted its position in shares of Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after acquiring an additional 9,508 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $18,048,000. State of Alaska Department of Revenue acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $2,628,000. Pacer Advisors Inc. purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $374,000. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $2,234,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of HIMS stock traded down $2.30 during midday trading on Monday, hitting $62.35. The company had a trading volume of 35,635,695 shares, compared to its average volume of 19,464,030. The stock has a market cap of $13.96 billion, a price-to-earnings ratio of 141.71 and a beta of 1.84. The company's 50 day simple moving average is $35.44 and its 200 day simple moving average is $33.90. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the prior year, the firm earned $0.05 EPS. Hims & Hers Health's quarterly revenue was up 110.7% on a year-over-year basis. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 47,534 shares of the company's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $58.25, for a total value of $2,768,855.50. Following the completion of the transaction, the chief executive officer now directly owns 285,194 shares in the company, valued at approximately $16,612,550.50. This represents a 14.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares of the company's stock, valued at approximately $9,549,268.05. This trade represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 751,215 shares of company stock valued at $32,900,637. 13.71% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $61.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Bank of America boosted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Piper Sandler reiterated a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price objective for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.